Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Merkel, Christian A ^a,b   da Silva Soares, Rafael B ^a,b   de Carvalho, Anna Carolina V ^a,b   Zanatta, Daniela B ^a,b   Bajgelman, Marcio C ^a,b   Fratini, Paula ^a,b   Costanzi Strauss, Eugenia ^a,b   Strauss, Bryan E ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b MCT   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOXORUBICIN; NUTLIN 3; PROTEIN P53; RETROVIRUS VECTOR; ANTINEOPLASTIC AGENT; CDKN2A PROTEIN, MOUSE; IMIDAZOLE DERIVATIVE; PIPERAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DRUG POTENTIATION; EMBRYO; GENE ACTIVITY; GENE EXPRESSION; GROWTH CURVE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MELANOMA B16; MOUSE; NONHUMAN; NORTHERN BLOTTING; PROTEIN FUNCTION; PROTEIN INDUCTION; RAT; REPORTER GENE; TRANSACTIVATION; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; WILD TYPE; ANIMAL; C57BL MOUSE; CELL SURVIVAL; DOSE RESPONSE; EXPERIMENTAL MELANOMA; FLUORESCENT ANTIBODY TECHNIQUE; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GENETICS; GLIOMA; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RETROVIRUS; TIME; TRANSCRIPTION INITIATION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FLUORESCENT ANTIBODY TECHNIQUE; GENE THERAPY; GENETIC VECTORS; GLIOMA; HUMANS; IMIDAZOLES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PIPERAZINES; RATS; RETROVIRIDAE; TIME FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSDUCTION, GENETIC; TRANSFECTION; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77953674449     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-316     Document Type: Article

References (31)

1. Kastan MB. Wild-type p53: tumors can't stand it. Cell 2007, 128:837-840. 10.1016/j.cell.2007.02.022, 17350571.
2. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006, 127:1323-1334. 10.1016/j.cell.2006.12.007, 17182091.
3. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665. 10.1038/nature05541, 17251932.
4. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660. 10.1038/nature05529, 17251933.
5. Giglia-Mari G, Sarasin A. TP53 mutations in human skin cancers. Hum Mutat 2003, 21:217-228. 10.1002/humu.10179, 12619107.
6. Polsky D, Bastian BC, Hazan C, Melzer K, Pack J, Houghton A, Busam K, Cordon-Cardo C, Osman I. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 2001, 61:7642-7646.
7. Sharpless E, Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003, 22:3092-3098. 10.1038/sj.onc.1206461, 12789286.
8. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007, 170:1445-1453. 10.2353/ajpath.2007.070011, 1854940, 17456751.
9. Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi ME, Janzer RC, Merlo A, Van Meir EG. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 2000, 19:3816-3822. 10.1038/sj.onc.1203700, 10949938.
10. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1999, 1:44-51. 10.1215/15228517-1-1-44, 1919466, 11550301.
11. Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 2008, 14:5318-5324. 10.1158/1078-0432.CCR-07-5136, 2676446, 18765522.
12. Lu W, Lin J, Chen J. Expression of p14ARF overcomes tumor resistance to p53. Cancer Res 2002, 62:1305-1310.
13. Tango Y, Fujiwara T, Itoshima T, Takata Y, Katsuda K, Uno F, Ohtani S, Tani T, Roth JA, Tanaka N. Adenovirus-mediated p14ARF gene transfer cooperates with Ad5CMV-p53 to induce apoptosis in human cancer cells. Hum Gene Ther 2002, 13:1373-1382. 10.1089/104303402760128595, 12162819.
14. Huang Y, Tyler T, Saadatmandi N, Lee C, Borgstrom P, Gjerset RA. Enhanced tumor suppression by a p14ARF/p53 bicistronic adenovirus through increased p53 protein translation and stability.[erratum appears in Cancer Res. 2003 Aug 15;63(16):5171]. Cancer Research 2003, 63:3646-3653.
15. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848. 10.1126/science.1092472, 14704432.
16. Vassilev LT. p53 Activation by small molecules: application in oncology. J Med Chem 2005, 48:4491-4499. 10.1021/jm058174k, 15999986.
17. Wade M, Wong ET, Tang M, Stommel JM, Wahl GM. Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem 2006, 281:33036-33044. 10.1074/jbc.M605405200, 16905769.
18. Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 2006, 281:33030-33035. 10.1074/jbc.C600147200, 16905541.
19. Ghosh M, Weghorst K, Berberich SJ. MdmX inhibits ARF mediated Mdm2 sumoylation. Cell Cycle 2005, 4:604-608.
20. Jackson MW, Lindstrom MS, Berberich SJ. MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation. J Biol Chem 2001, 276:25336-25341. 10.1074/jbc.M010685200, 11297540.
21. Strauss BE, Costanzi-Strauss E. pCLPG: a p53-driven retroviral system. Virology 2004, 321:165-172. 10.1016/j.virol.2003.12.021, 15051377.
22. Strauss BE, Bajgelman MC, Costanzi-Strauss E. A novel gene transfer strategy that combines promoter and transgene activities for improved tumor cell inhibition. Cancer Gene Ther 2005, 12:935-946. 10.1038/sj.cgt.7700846, 15905860.
23. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 1987, 7:379-387. 365079, 3031469.
24. Naviaux RK, Costanzi E, Haas M, Verma IM. The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. Journal of Virology 1996, 70:5701-5705. 190538, 8764092.
25. Bajgelman MC, Costanzi-Strauss E, Strauss BE. Exploration of critical parameters for transient retrovirus production. J Biotechnol 2003, 103:97-106. 10.1016/S0168-1656(03)00103-2, 12814868.
26. Bajgelman MC, Strauss BE. The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53. Prostate 2006, 66:1455-1462. 10.1002/pros.20462, 16741917.
27. Strauss BE, Fontes RB, Lotfi CF, Skorupa A, Bartol I, Cipolla-Neto J, Costanzi-Strauss E. Retroviral transfer of the p16INK4a cDNA inhibits C6 glioma formation in Wistar rats. Cancer Cell Int 2002, 2:2. 10.1186/1475-2867-2-2, 116432, 11983028.
28. Gjerset RA. DNA damage, p14ARF, nucleophosmin (NPM/B23), and cancer. J Mol Histol 2006, 37:239-251. 10.1007/s10735-006-9040-y, 16855788.
29. Lee C, Smith BA, Bandyopadhyay K, Gjerset RA. DNA damage disrupts the p14ARF-B23(nucleophosmin) interaction and triggers a transient subnuclear redistribution of p14ARF. Cancer Res 2005, 65:9834-9842. 10.1158/0008-5472.CAN-05-1759, 16267006.
30. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000, 14:34-44. 316350, 10640274.
31. Wei X, Yu ZK, Ramalingam A, Grossman SR, Yu JH, Bloch DB, Maki CG. Physical and functional interactions between PML and MDM2. J Biol Chem 2003, 278:29288-29297. 10.1074/jbc.M212215200, 12759344.